Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Sphingosine kinase 1 (SK1) is a proto-oncogenic enzyme implicated in tumor progression, chemoresistance, and poor prognosis.
• SK1 inhibition is a validated strategy to chemosensitize solid tumors, but clinical safety and efficacy data for inhibitors are limited.

Purpose of the Study:

• To design, synthesize, and evaluate a novel, specific SK1 inhibitor with a favorable toxicity profile.
• To assess the in vitro and in vivo anticancer activity and chemosensitizing potential of the new inhibitor.

Main Methods:

• Field template molecular modeling was employed for the rational design of new SK1 inhibitors.
• Lead compounds underwent rigorous testing in cell-based assays and preclinical mouse cancer models.

Main Results:

• Field template analysis identified six potential SK1 inhibitors, with two demonstrating potent SK1 inhibitory activity in vitro.
• The compound SK-F significantly reduced cancer cell viability in vitro and sensitized mouse breast tumors to docetaxel (DTX) in vivo.
• SK-F exhibited a low toxicity profile when administered in combination with DTX.

Conclusions:

• Field template screening successfully identified SK-F, a novel SK1 inhibitor with demonstrated in vitro and in vivo antitumour activity.
• SK-F shows promise as a therapeutic agent that enhances docetaxel efficacy in solid tumors without significant overt toxicity.